To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(11 sites)
China
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing Municipality Children's Hospital Affiliated to the Capital Institute of Pediatrics, Beijing, Beijing Municipality Children's Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality Sun Yat-Sen Memorial Hpsipital,Sun Yat-Sen Unniversity, Guangzhou, Guangdong The First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong Shenzhen Children's Hospital, Shenzhen, Guangdong Henan Children's Hospital Zhengzhou Children's Hospital, Zhengzhou, Henan Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei West China Second University Hospital,Sihuan University/West China women's and Children's Hospital, Chengdu, Sichuan Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Children's Hospital of Soochow University, Suzhou Last updated January 2025